This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Regenerative Medicine Markets

5. Stem Cell Industry Highlights, 2012 1045.1 Business Development 1045.2 Clinical Trials 1045.3 Market Authorization 1045.4 Regulations 1055.5 Capital Market and Finances 1055.6 Investments in Xeno-Cell Therapy 1055.7 Collaborations in Stem Cell Science 1065.7.1 California Institute for Regenerative Medicine (CIRM) 1065.7.2 The International Translational Regenerative Medicine Center 111

6. Regenerative Medicines: A Brief Update from Selected Countries 1126.1 U.S. 1126.1.1 Key Institutions 1126.1.1.1 California Institute for Regenerative Medicine 1126.1.1.2 The New York Stem Cell Foundation 1126.1.1.3 NIH Center for Regenerative Medicine 1126.1.2 Innovative Company 1126.1.2.1 Aastrom Biosciences 1126.2 Canada 1136.2.1 Key Institutions 1136.2.1.1 Institute of Biomaterials & Biomedical Engineering, University of Toronto 1136.2.1.2 Terry Fox Research Institute 1136.2.1.3 Institute for Research in Immunology and Cancer, University of Montreal 1136.2.2 Innovative Companies 1136.2.2.1 Northern Therapeutics 1136.2.2.2 Octane Biotech 1136.3 U.K. 1136.3.1 Key Institutions 1146.3.1.1 Loughborough University 1146.3.1.2 U.K. Stem Cell Foundation 1146.3.1.3 University College, London 1146.3.2 Innovative Companies 1146.3.2.1 Intercytex 1146.3.2.2 Azellon Cell Therapeutics 1156.3.2.3 Cell Medica 1156.4 Sweden 1156.4.1 Key Institutions 1156.4.1.1 Karolinska Institutet 1156.4.1.2 The University of Lund 1156.4.2 Innovative Companies 1166.4.2.1 Vitrolife 1166.4.2.2 Cellartis 1166.4.2.3 Biolamina 1166.5 Brazil 1166.5.1 Key Institutions 1166.5.1.1 Universidade de SaoPaulo 1166.5.1.2 Fiocruz and Hospital Sao Rafael 1166.5.1.3 Universidade Federal do Rio de Janeiro 1176.5.1.4 Pontificia Universidade Catolica do Parana 1176.5.2 Innovative Company 1176.5.2.1 Excellion & CellPraxys 117

7. Market Analysis for Regenerative Medicine Sector 1187.1 Scope of this Chapter 1187.2 Opportunities for RM Products 1187.3 Commercial RM Products 1197.3.1 Leading Commercial Cell Therapy Products 1197.3.2 FDA Approved Cell-Based Products 1207.3.3 Growth Spurt by Regenerative Medicine (RM) 1217.4 Global Market for Tissue-Engineered Products 1227.4.1 Tissue Engineering and Stem Cell Industry 1247.5 Market for Stem Cell Therapy in Cardiology 1247.6 Market for RM Products in Orthopedics 1267.6.1 No Strong Alternatives for Medtronic's INFUSE 1277.6.2 Demineralized Bone Matrix (DBM) 1287.6.3 The Unproven Stem Cells in Orthopedics 1287.6.4 Future of Bone Replacement Market 1297.7 Global RM Market for Neurology Products 1307.8 Market for RM Dental Products 1317.9 Market for RM Cancer Products 132 7.10 RM Market for Urology Products 1337.11 Global Market for Skin Products 1347.12 Overall Global RM Market 1357.13 U.S. Market for Tissue-Engineered Skin 1367.14 U.S. RM Market for Orthopedic/Spine Products 1387.15 U.S. RM Market for Nerve Repair Products 1407.16 U.S. RM Market for Cardiovascular and Stroke Products 1417.17 U.S. Market for Anti-Inflammatory RM Products 1427.18 U.S. Market for RM Products in Diabetes 1427.19 Overall U.S. Regenerative Medicine Market 1437.19.1 U.S. RM Market by Segment 144

8. Stem Cell Industry 1468.1 Global Market for Stem cells 1478.2 Stem Cell Use in the U.S. 1488.2.1 Autologous Stem Cell Use in the U.S. 1488.2.2 U.S. Stem Cell Market Overview 1498.2.2.1 Potential U.S. Population for Cell-Based Therapies 1508.2.3 U.S. Market for Stem cells 1518.3 European Market for Stem Cells 1538.3.1 Autologous and Allogeneic Cell Therapy Companies in Europe 1548.4 Asia-Pacific Market for Stem Cells 1558.5 Autologous Cell Therapy 1568.5.1 Commercially Available Autologous Treatments 1568.5.1.1 Autologous Cell Therapy for Alzheimer's disease 1578.5.1.2 Autologous Cell Therapy for Multiple Sclerosis 1578.5.1.3 Autologous Cell Therapy for Wound Healing 1578.5.1.4 Autologous Therapy for Cosmetic Surgery 158

9. Business Models and Requirements for a Successful Regenerative Medicine Industry 1599.1 Scope of this Chapter 1599.2 Business Models in Regenerative Medicine 1599.2.1 Current Model for Autologous Cell Therapies 1609.2.2 Current Models for Allogeneic Cell Therapies 1619.3 Key Factors for Successful Business Models for Cell Therapies 1639.4 Requirements for Commercial Manufacturing of Cell Therapy Products 1639.4.1 Elements of Commercial Manufacturing 1639.4.1.1 Regulatory Requirements 1639.4.1.2 Manufacturing Process Scale 1649.4.1.3 In-House Manufacturing 1649.4.1.4 Contract Manufacturing: Commercial and Academic 165

3 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs